BFM
IMUX icon

Boothbay Fund Management’s Immunic IMUX Stock Holding History

Boothbay Fund Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed -$303K – 858
2018
Q2 		$303K Buy
+1
New +$2.31K 0.03% 470

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Boothbay Fund Management's IMUX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Immunic (IMUX) in Q2 2026: 13,057 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #1935 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in IMUX as recently as Q4 2025.

Boothbay Fund Management first reported a position in IMUX in Q3 2018 and has held it in 18 quarters since. The position peaked at $699K in Q3 2024. 56 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Boothbay Fund Management held 13,057 shares of Immunic worth $201K as of Q2 2026.
  • Immunic was a new Boothbay Fund Management position in Q2 2026.
  • Immunic made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1935 holding.
  • Boothbay Fund Management first reported a position in Immunic in Q3 2018 and has held it in 18 quarters since.
  • Boothbay Fund Management's Immunic position peaked at $699K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.